Clinical trial: Oral drug keeps cancer treatment on track for patients who develop persist

20 de July de 2026 6 leituras

Clinical trial: Oral drug keeps cancer treatment on track for patients who develop persistently low platelet counts. In a phase 2 clinical trial, Mass General Brigham Cancer Institute researchers found that the oral drug avatrombopag was safe and effective in managing persistent chemotherapy-induced thrombocytopenia (CIT) in more than half of patients with gastrointestinal cancers, offering a potential new option for managing a common and challenging complication of cancer treatment.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: In a phase 2 clinical trial, Mass General Brigham Cancer Institute researchers found that the oral drug avatrombopag was safe and effective in managing persistent chemotherapy-induced thrombocytopenia (CIT) in more than half of patients with gastrointestinal cancers, offering a potential new option for managing a common and challenging complication of cancer treatment. Their work is published in the Journal of Clinical Oncology.

Ponto de atenção: clinical.
Ponto de atenção: trial.
Ponto de atenção: oral.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Saúde.

#clinical #drug #keeps #oral #trial

Matéria produzida com curadoria editorial assistida por IA, a partir de pauta de medicalxpress.com.